In Brief
Refine Search
Pharmaceutical
Takeda Pharmaceutical has announced it will issue $5.5 billion of US-dollar denominated senior notes to help pay for its purchase of Shire. 20 November 2018
Pharmaceutical
Ireland-headquartered inflammasone company Inflazome today announces the successful completion of a Series B financing round of 40 million euros ($46 million). 20 November 2018
Pharmaceutical
Japan’s Chugai Pharmaceutical has filed a patent infringement lawsuit against Alexion Pharmaceuticals in the in the US District Court for Delaware. 19 November 2018
Pharmaceutical
Saying it is “in the spirit of providing greater transparency for patients,” US pharma giant Pfizer announced on Friday that it plans to maintain the current list prices for about 90% of its medicines. 17 November 2018
Pharmaceutical
The European Commission has approved French drugmaker Ipsen’s Cabometyx (cabozantinib) as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. 15 November 2018
Pharmaceutical
Shares of Japanese pharma major Daiichi Sankyo were down 5.3% at 4,226 yen today, after it announced that Japan Vaccine, its joint venture with GlaxoSmithKline, will be dissolved. 14 November 2018
Pharmaceutical
Angion Biomedica and Sinovant Sciences have entered into a collaboration and license agreement for BB3, Angion's investigational small molecule mimetic of hepatocyte growth factor (HGF). 13 November 2018
Pharmaceutical
Theravance Biopharma and Mylan have won US approval for Yupelri (revefenacin) for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). 12 November 2018
Pharmaceutical
German science and technology company Merck KGaA today signed an agreement with the Guangzhou Development District on innovation development in Southern China. 12 November 2018
Pharmaceutical
Takeda Pharmaceutical has announced it will hold an extraordinary general meeting of shareholders to vote on its proposed acquisition of Shire on 5 December. 12 November 2018
Pharmaceutical
AcelRx Pharmaceuticals today announced the pricing of its previously announced underwritten public offering of 12,698,412 shares of its common stock, at a public offering price of $3.15 per share. 9 November 2018
Pharmaceutical
The European Commission has authorized an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’), which is marketed by UK pharma major GlaxoSmithKline. 9 November 2018
Pharmaceutical
Japan’s Eisai has commenced full-scale operation of its new Suzhou, China-based plant. The facility is around five times larger than the former plant, and will be used to manufacture oral solid dose products. 8 November 2018
Pharmaceutical
China has issued a clinical study guideline for bipolar disorder and schizophrenia drugs. 8 November 2018
Pharmaceutical
Takeda Pharmaceutical has launched Entyvio (vedolizumab) for the treatment of patients with moderately to severely active ulcerative colitis (UC) in Japan. 7 November 2018
Pharmaceutical
Heptares Therapeutics, a subsidiary of Tokyo’s Sosei Group, has entered into a new collaboration with Germany-based DyNAbind. 7 November 2018
Pharmaceutical
Phase II data on cefiderocol (S-649266), a new drug from Japanese pharma company Shionogi for the treatment of urinary tract infection in patients at risk of multidrug-resistant Gram-negative infections, has appeared in The Lancet Infectious Diseases journal. 6 November 2018
Pharmaceutical
Ireland-headquartered Theravance Biopharma announced the sale of its proprietary antibiotic, Vibativ (telavancin), to Cumberland Pharmaceuticals. 6 November 2018
Pharmaceutical
Eli Lilly and NextCure have entered into a collaboration to discover new immuno-oncology therapies, utilizing NextCure's proprietary FIND-IO platform. 6 November 2018
Pharmaceutical
German family-owned drugmaker Grünenthal has acquired additional global commercial rights for the dermal pain patch Qutenza (8% capsaicin) from USA-based Acorda Therapeutics. 5 November 2018
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics represent, fundamentally transforming how cancer is treated. 3 January 2025
Pharmaceutical
Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that its experimental depression treatment failed in the first of three studies planned by the biotech company. 3 January 2025
Pharmaceutical
Hutchmed has announced agreements to divest its 45% equity stake in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for $608 million in cash. The buyers are GP Health Service Capital and Shanghai Pharmaceuticals. 2 January 2025
Pharmaceutical
Kazia Therapeutics, an oncology-focused Australian drug developer, has been advised by the US Food and Drug Administration (FDA) that accelerated approval for its brain cancer drug, paxalisib, is unlikely. 2 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib, an oral RAF/MEK clamp, in combination with defactinib. 2 January 2025
Pharmaceutical
The new $2,000 cap on out-of-pocket costs for prescription drugs went into effect as of January 1, 2025, the US Department of Health and Human Services (HHS) Secretary Xavier Becerra has announced. 2 January 2025
Pharmaceutical
The market for artificial intelligence (AI) in cancer care is projected to grow from $2.2 billion in 2024 to $6.3 billion by 2029, reflecting a growth rate of 23.1%, according to a recent study by BCC Research. 31 December 2024
Pharmaceutical
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Winrevair (sotatercept) to treat pulmonary arterial hypertension (PAH), from US pharma giant Merck & Co. 31 December 2024
Pharmaceutical
US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 (dextromethorphan-bupropion). 31 December 2024
Pharmaceutical
It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with Denmark’s Novo Nordisk continues. 31 December 2024
Pharmaceutical
The US Food and Drug Administration (FDA) is reopening the comment period for the Federal Register notice (FRN), “Evaluating the Immunogenicity Risk of Host Cell Proteins in Follow-on Recombinant Peptide Products: Establishment of a Public Docket: Request for Information and Comments” due to high interest from industry. 31 December 2024
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued a warning urging the public to avoid purchasing weight-loss medicines without a prescription. 30 December 2024
Pharmaceutical
For many in the life sciences, the year gone by has been marked by volatility across a range of metrics, as political and economic disruptions threaten to upend the standard operating model. 30 December 2024
Pharmaceutical
China’s National Medical Products Administration (NMPA) has recently approved Zorifer (zorifertinib), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) specifically for the treatment of non-small cell lung cancer (NSCLC) with CNS metastases. 30 December 2024
Pharmaceutical
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the use of Hyqvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) in patients with agammaglobulinemia or hypogammaglobulinemia disorders, from domestic drug giant Takeda Pharma 27 December 2024
Pharmaceutical
Japanese drugmaker Kaken Pharmaceutical has entered into a license agreement with US healthcare giant Johnson & Johnson for the global development, manufacturing and commercialization of a STAT6 program that Kaken is developing. 27 December 2024
Pharmaceutical
Akums, India’s largest contract development and manufacturing organization (CDMO), has signed a strategic agreement with an undisclosed global pharmaceutical company. 27 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze